Madrigal Pharmaceuticals Stock Performance
| MDGL Stock | USD 347.45 18.21 5.53% |
On a scale of 0 to 100, Madrigal Pharmaceuticals holds a performance score of 9. The company secures a Beta (Market Risk) of 0.39, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Madrigal Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Madrigal Pharmaceuticals is expected to be smaller as well. Please check Madrigal Pharmaceuticals' downside variance, day median price, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Madrigal Pharmaceuticals' current price movements will revert.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite quite unfluctuating technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.53 | Five Day Return 19.71 | Year To Date Return 53.16 | Ten Year Return 217.16 | All Time Return 9.21 |
Last Split Factor 1:35 | Dividend Date 2016-07-25 | Last Split Date 2016-07-25 |
1 | Disposition of 6363 shares by William Sibold of Madrigal Pharmaceuticals at 243.83 subject to Rule 16b-3 | 09/09/2024 |
2 | Disposition of 15000 shares by Craves Fred B of Madrigal Pharmaceuticals subject to Rule 16b-3 | 09/13/2024 |
3 | Disposition of 18917 shares by Taub Rebecca of Madrigal Pharmaceuticals at 245.3356 subject to Rule 16b-3 | 09/20/2024 |
4 | Disposition of 000 shares by Craves Fred B of Madrigal Pharmaceuticals subject to Rule 16b-3 | 10/04/2024 |
5 | Acquisition by Friedman Paul A of 26270 shares of Madrigal Pharmaceuticals at 9.45 subject to Rule 16b-3 | 10/22/2024 |
6 | Madrigal Stock Soars 23 percent as NASH Drug Rezdiffra Crushes Expectations | 11/04/2024 |
7 | Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences | 11/06/2024 |
8 | Heres Why Madrigal is a Great Momentum Stock to Buy | 11/07/2024 |
9 | Avoro Capital Advisors LLC Adjusts Stake in Spyre Therapeutics Inc | 11/14/2024 |
10 | Disposition of 945 shares by Taub Rebecca of Madrigal Pharmaceuticals at 244.7881 subject to Rule 16b-3 | 11/15/2024 |
11 | Madrigal shares hold as Cowen maintains price target on new data | 11/20/2024 |
12 | Why Is Madrigal Pharmaceuticals, Inc. Among the Worst Performing Biotech Stocks in 2024 | 11/21/2024 |
| Begin Period Cash Flow | 331.5 M |
Madrigal |
Madrigal Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 25,481 in Madrigal Pharmaceuticals on August 27, 2024 and sell it today you would earn a total of 9,264 from holding Madrigal Pharmaceuticals or generate 36.36% return on investment over 90 days. Madrigal Pharmaceuticals is currently generating 0.5815% in daily expected returns and assumes 4.6077% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Madrigal, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Madrigal Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Madrigal Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Madrigal Pharmaceuticals, and traders can use it to determine the average amount a Madrigal Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1262
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MDGL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.61 actual daily | 41 59% of assets are more volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Madrigal Pharmaceuticals is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Madrigal Pharmaceuticals by adding it to a well-diversified portfolio.
Madrigal Pharmaceuticals Fundamentals Growth
Madrigal Stock prices reflect investors' perceptions of the future prospects and financial health of Madrigal Pharmaceuticals, and Madrigal Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Madrigal Stock performance.
| Return On Equity | -1.3 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (1.87) % | ||||
| Current Valuation | 6.7 B | ||||
| Shares Outstanding | 21.81 M | ||||
| Price To Earning | (13.96) X | ||||
| Price To Book | 9.75 X | ||||
| Price To Sales | 98.66 X | ||||
| EBITDA | (379.97 M) | ||||
| Net Income | (373.63 M) | ||||
| Cash And Equivalents | 211.77 M | ||||
| Cash Per Share | 12.38 X | ||||
| Total Debt | 117.19 M | ||||
| Debt To Equity | 0.59 % | ||||
| Current Ratio | 2.55 X | ||||
| Book Value Per Share | 35.64 X | ||||
| Cash Flow From Operations | (324.23 M) | ||||
| Earnings Per Share | (25.02) X | ||||
| Market Capitalization | 7.58 B | ||||
| Total Asset | 640.55 M | ||||
| Retained Earnings | (1.34 B) | ||||
| Working Capital | 518.73 M | ||||
| Current Asset | 363.58 K | ||||
| Current Liabilities | 49.28 M | ||||
About Madrigal Pharmaceuticals Performance
By examining Madrigal Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Madrigal Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Madrigal Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.58) | (0.61) | |
| Return On Capital Employed | (0.73) | (0.77) | |
| Return On Assets | (0.58) | (0.61) | |
| Return On Equity | (0.92) | (0.88) |
Things to note about Madrigal Pharmaceuticals performance evaluation
Checking the ongoing alerts about Madrigal Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Madrigal Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Madrigal Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (373.63 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38. | |
| Madrigal Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Why Is Madrigal Pharmaceuticals, Inc. Among the Worst Performing Biotech Stocks in 2024 |
- Analyzing Madrigal Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Madrigal Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Madrigal Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Madrigal Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Madrigal Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Madrigal Pharmaceuticals' stock. These opinions can provide insight into Madrigal Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (25.02) | Revenue Per Share 3.705 | Return On Assets (0.52) | Return On Equity (1.30) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.